{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:22:14Z","timestamp":1794666134797,"version":"4.9.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Sepsis, a condition characterized by the excessive release of inflammatory mediators, significantly alters body composition and physiology and is potentially altered by intensive care therapy. The present study aimed to expand a comprehensive physiologically based pharmacokinetic (PBPK) model for healthy individuals based on physiological changes associated with conditions in critically ill adult patients with sepsis and to validate its accuracy using fosfomycin as a therapeutically relevant medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted using various online databases, and pharmacokinetic (PK) data for fosfomycin were gathered. PKSim, a PBPK modeling program, was then used to construct and evaluate drug-specific and intravenous models. The robustness of the model was then evaluated for each of the crucial PK parameters using the average fold error, predicted\/observed ratios, and visual predictive checks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Analysis of the performance of the model showed that all PK parameters were within the 2-fold allowable error range. The average fold error value, which is an indication of how much model predictions normally differ from the reported value, was 0.81 after intravenous infusions in healthy individuals, which validates the proposed fosfomycin model. In patients with sepsis, the R\n                      <jats:sub>Pre\/obs<\/jats:sub>\n                      ratio was predicted to be 310.2 mcg\/mL, which is comparable to the value of 332.3 mcg\/mL from the literature. In addition, the results were further analyzed to show how sepsis affects the area under the systemic concentration over a time curve from zero to infinity (AUC\n                      <jats:sub>0-\u221e<\/jats:sub>\n                      ). The results of this analysis serve as a reference for clinicians determining the optimal dosage of fosfomycin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The proposed model, which is effective in predicting fosfomycin PK variations in both healthy and critically ill patients with sepsis, will aid in optimizing the dose of fosfomycin for critically ill patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001423","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T15:00:12Z","timestamp":1767193212000},"page":"497-505","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing the Clinical Exposure of Fosfomycin in Critically Ill Adult Septic Patients: A Physiologically Based Pharmacokinetic Modeling"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2559-4405","authenticated-orcid":false,"given":"Abdul Wasay","family":"Sherazi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"issue":"suppl 2","key":"R1-20261114","first-page":"ii11","article-title":"Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective)","volume":"66","author":"Daniels","year":"2011","journal-title":"J Antimicrobl Chemother."},{"key":"R2-20261114","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","article-title":"Sepsis in European intensive care units: results of the SOAP study","volume":"34","author":"Vincent","year":"2006","journal-title":"Crit Care Med."},{"key":"R3-20261114","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1056\/NEJMoa022139","article-title":"The epidemiology of sepsis in the United States from 1979 through 2000","volume":"348","author":"Martin","year":"2003","journal-title":"N Engl J Med."},{"key":"R4-20261114","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/01.CCM.0000261890.41311.E9","article-title":"Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003","volume":"35","author":"Dombrovskiy","year":"2007","journal-title":"Crit Care Med."},{"key":"R5-20261114","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"R6-20261114","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMcibr1007320","article-title":"Sepsis and endothelial permeability","volume":"363","author":"Lee","year":"2010","journal-title":"N Engl J Med."},{"key":"R7-20261114","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.1097\/01.CCM.0000081431.50015.46","article-title":"Vessel injury and capillary leak","volume":"31","author":"Fishel","year":"2003","journal-title":"Crit Care Med."},{"key":"R8-20261114","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0026-895X(25)13247-1","article-title":"Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture","volume":"44","author":"Abdel-Razzak","year":"1993","journal-title":"Mol Pharmacol."},{"key":"R9-20261114","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/bja\/85.4.599","article-title":"The role of albumin in critical illness","volume":"85","author":"Nicholson","year":"2000","journal-title":"Br J Anaesth."},{"key":"R10-20261114","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving Sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med."},{"key":"R11-20261114","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200241140-00002","article-title":"Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock","volume":"41","author":"De Paepe","year":"2002","journal-title":"Clin Pharmacokinet."},{"key":"R12-20261114","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.2174\/138920111798808211","article-title":"The effect of critical illness on drug distribution","volume":"12","author":"Gonzalez","year":"2011","journal-title":"Curr Pharm Biotechnol."},{"key":"R13-20261114","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.2174\/138920111798808248","article-title":"Physiological changes in the critically ill patient with sepsis","volume":"12","author":"Hosein","year":"2011","journal-title":"Curr Pharm Biotechnol."},{"key":"R14-20261114","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"R15-20261114","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1093\/jac\/dkaa294","article-title":"Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection","volume":"75","author":"Kuiper","year":"2020","journal-title":"J Antimicrob Chemother."},{"issue":"suppl 1","key":"R16-20261114","first-page":"141","article-title":"Pharmacokinetics of fosfomycin","volume":"23","author":"Kirby","year":"1977","journal-title":"Chemotherapy"},{"key":"R17-20261114","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2147\/TCRM.S199119","article-title":"Fosfomycin: the characteristics, activity, and use in critical care","volume":"15","author":"Hashemian","year":"2019","journal-title":"Ther Clin Risk Manag."},{"key":"R18-20261114","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/phar.1434","article-title":"Fosfomycin for the treatment of resistant gram\u2010negative bacterial infections: insights from the Society of Infectious Diseases Pharmacists","volume":"34","author":"Reffert","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R19-20261114","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/0255-0857.195379","article-title":"Exploring the hidden potential of fosfomycin for the fight against severe Gram-negative infections","volume":"34","author":"Saiprasad","year":"2016","journal-title":"Indian J Med Microbiol."},{"key":"R20-20261114","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/03009739509178895","article-title":"Torsten Teorell, the father of pharmacokinetics","volume":"100","author":"Paalzow","year":"1995","journal-title":"Upsala J Med Sci."},{"key":"R21-20261114","first-page":"205","article-title":"Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration","volume":"57","author":"Teorell","year":"1937","journal-title":"Arch internationales de pharmacodynamie de therapie"},{"key":"R22-20261114","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"R24-20261114","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jps.24214","article-title":"A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation","volume":"104","author":"Thiel","year":"2015","journal-title":"J Pharm Sci."},{"key":"R25-20261114","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1208\/s12248-013-9505-3","article-title":"A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy","volume":"15","author":"Xia","year":"2013","journal-title":"AAPS J."},{"key":"R26-20261114","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","article-title":"Development and evaluation of a generic physiologically based pharmacokinetic model for children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clin Pharmacokinet."},{"key":"R27-20261114","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/jps.1076","article-title":"Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model","volume":"90","author":"Bj\u00f6rkman","year":"2001","journal-title":"J Pharm Sci."},{"key":"R28-20261114","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/DDDT.S297981","article-title":"Development and evaluation of a physiologically based pharmacokinetic drug-disease model of propranolol for suggesting model informed dosing in liver cirrhosis patients","volume":"15","author":"Kalam","year":"2021","journal-title":"Drug Des Devel Ther."},{"key":"R29-20261114","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/17425255.2021.1921145","article-title":"Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug-drug interaction in healthy adults and its extrapolation to virtual chronic heart failure patients for dose optimization","volume":"17","author":"Rasool","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R30-20261114","doi-asserted-by":"crossref","first-page":"1200828","DOI":"10.3389\/fphar.2023.1200828","article-title":"Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing","volume":"14","author":"Alasmari","year":"2023","journal-title":"Front Pharmacol."},{"key":"R31-20261114","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40262-016-0475-3","article-title":"Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients","volume":"56","author":"Radke","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R32-20261114","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00134-010-2089-9","article-title":"Sepsis as a cause and consequence of acute kidney injury: program to improve care in acute renal disease","volume":"37","author":"Mehta","year":"2011","journal-title":"Intensive Care Med."},{"key":"R33-20261114","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/cc11381","article-title":"Clinical review: the liver in sepsis","volume":"16","author":"Nesseler","year":"2012","journal-title":"Crit Care"},{"key":"R34-20261114","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/psp4.13097","article-title":"Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment","volume":"13","author":"Darlow","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"R35-20261114","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/bcp.14456","article-title":"Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics","volume":"87","author":"Martins","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"R36-20261114","first-page":"98","article-title":"Physiologically based pharmacokinetic modeling in regulatory decision\u2010making at the European Medicines Agency","volume":"102","author":"Luzon","year":"2017","journal-title":"Clinpharmacol Ther."},{"issue":"suppl 1","key":"R37-20261114","first-page":"10","article-title":"Pharmacokinetic comparison between fosfomycin and other phosphonic acid derivatives","volume":"36","author":"Bergan","year":"1990","journal-title":"Chemotherapy"},{"key":"R38-20261114","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"R39-20261114","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/jac\/dkh158","article-title":"Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis","volume":"53","author":"Pfausler","year":"2004","journal-title":"J Antimicrob Chemother."},{"key":"R40-20261114","first-page":"297","article-title":"Pharmacokinetic profile of fosfomycin trometamol","volume":"39","author":"Bergan","year":"1993","journal-title":"Chemotherapy"},{"key":"R41-20261114","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1128\/AAC.44.10.2728-2732.2000","article-title":"Distribution and antimicrobial activity of fosfomycin in the interstitial fluid of human soft tissues","volume":"44","author":"Frossard","year":"2000","journal-title":"Antimicrob Agents Chemother."},{"key":"R42-20261114","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"R43-20261114","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Programs Biomed."},{"key":"R44-20261114","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/dkl251","article-title":"Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration","volume":"58","author":"Gattringer","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"R45-20261114","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkq070","article-title":"Extracellular concentrations of fosfomycin in lung tissue of septic patients","volume":"65","author":"Matzi","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R46-20261114","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jac\/dkg187","article-title":"Target site penetration of fosfomycin in critically ill patients","volume":"51","author":"Joukhadar","year":"2003","journal-title":"J Antimicrob Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:00:16Z","timestamp":1794664816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001423","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"2025-08-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}